Evogliptin (Suganon) is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor being developed by Dong-A ST for the treatment of type 2 diabetes mellitus. Evogliptin was approved in South Korea on 2 October 2015 for blood glucose lowering in patients with type 2 diabetes mellitus inadequately controlled by diet and exercise alone or by metformin plus diet and exercise. In July 2015, Dong-A ST signed a licensing out agreement for evogliptin with Geropharm for Russia, Ukraine and Kazakhstan markets. In April 2015, Dong-A ST signed a licensing agreement with Eurofarma Laboratorios of Brazil for 17 Latin America countries including Mexico. Evogliptin is a potent DPP-4 inhibitor with a 50 % inhibitory concentration (IC50) against soluble human DPP-4 of 0.98 nmol/L and an IC50 of 1.26 nmol/L against membrane-bound human DPP-4. It displayed 6000-fold higher potency for human DPP-4 than for human DPP-8 and DPP-9, and 20,000-fold greater potency for DPP-4 than for DPP-1, DPP-2 and other closely-related enzymes. Evogliptin is effective in improving glycosylated hemoglobin (HbA1c) and fasting plasma glucose without inducing hypoglycemia events, which potentially can improve adherence and prevent complications. It is also found that evogliptin has benefits on insulin secretory and β-cell functions. Based on the current clinical data, evogliptin has a neutral effect on body weight. These attributes contribute to the clinical practice in monotherapy or in combination with other antidiabetic agents. Evogliptin was generally well tolerated in clinical trials.